A study to understand the rate at which the oral granules of the TAF drug are absorbed in healthy adults - Trial 2019-003269-16
Access comprehensive clinical trial information for 2019-003269-16 through Pure Global AI's free database. This phase not specified trial is sponsored by Gilead Sciences, Inc. and is currently status unknown. The study focuses on Chronic Hepatitis B.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
2019-003269-16
Trial Details
EU Clinical Trials Register • 2019-003269-16
A study to understand the rate at which the oral granules of the TAF drug are absorbed in healthy adults
Study Focus
Sponsor & Location
Gilead Sciences, Inc.
Timeline & Enrollment
N/A
N/A
N/A
Primary Outcome
Subjects who meet any of the following exclusion criteria will not be enrolled in this study:
ICD-10 Classifications
Acute hepatitis B
Chronic viral hepatitis B without delta-agent
Acute delta-(super)infection in chronic hepatitis B
Chronic viral hepatitis B without delta-agent : other and unspecified phase
Chronic viral hepatitis B without delta-agent : immune-tolerant phase
Data Source
EU Clinical Trials Register
2019-003269-16
Non-Device Trial